Lipid Management in Patients Presenting With Acute Coronary Syndromes: A Review.

Abstract

Despite many improvements in its prevention and management, acute coronary syndrome (ACS) remains a major cause of morbidity and mortality in the developed world. Lipid management is an important part of secondary prevention after ACS, but many patients currently remain undertreated and do not attain guideline-recommended levels of low-density lipoprotein cholesterol reduction. This review details the current state of evidence on lipid management in patients presenting with ACS, provides directions for identification of patients who may benefit from early escalation of lipid-lowering therapy, and discusses novel lipid-lowering medication that is currently under investigation in clinical trials. Moreover, a treatment algorithm aimed at attaining guideline-recommended low-density lipoprotein cholesterol levels is proposed. Despite important advances in the initial treatment and secondary prevention of ACS, ≈20% of ACS survivors experience a subsequent ischemic cardiovascular event within 24 months, and 5-year mortality ranges from 19% to 22%. Knowledge of the current state of evidence-based lipid management after ACS is of paramount importance to improve outcomes after ACS.

• Authors: Bimmer E Claessen, Paul Guedeney, C Michael Gibson, Dominick J Angiolillo, Davide Cao, Norman Lepor, Roxana Mehran
• Journal: Journal of the American Heart Association (J Am Heart Assoc) Vol. 9 Issue 24 Pg. e018897 (12 15 2020) ISSN: 2047-9980 [Electronic] England
• PMID: 33289416 (Publication Type: Journal Article, Review)

Chemical References

• ALN-PCS
• Anticholesteremic Agents
• Cholesterol, LDL
• Dicarboxylic Acids
• Fatty Acids
• Hydroxymethylglutaryl-CoA Reductase Inhibitors
• Hypolipidemic Agents
• Lipids
• PCSK9 Inhibitors
• RNA, Small Interfering
• 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid
• Eicosapentaenoic Acid
• PCSK9 protein, human
• Ezetimibe

Topics

• Acute Coronary Syndrome (drug therapy, prevention & control)
• Adult
• Aged
• Aged, 80 and over
• Anticholesteremic Agents (therapeutic use)
• Cholesterol, LDL (blood)
• Cost-Benefit Analysis (economics)
• Dicarboxylic Acids (therapeutic use)
• Eicosapentaenoic Acid (therapeutic use)
• Ezetimibe (therapeutic use)
• Fatty Acids (therapeutic use)
• Female
• Humans
• Hydroxymethylglutaryl-CoA Reductase Inhibitors (adverse effects, therapeutic use)
• Hypolipidemic Agents (therapeutic use)
• Lipids (adverse effects, blood)
• Male
• Middle Aged
• Myocardial Ischemia (epidemiology, mortality)
• PCSK9 Inhibitors
• Practice Guidelines as Topic
• RNA, Small Interfering (therapeutic use)
• Risk Reduction Behavior
• Secondary Prevention